The Brain Protection Study That Should Change How You Think About Coffee
Key Takeaways
- The longest clinical trial of Lion's Mane ever conducted (49 weeks) showed the supplementation group improved while the placebo group declined — two trajectories moving in opposite directions.
- Lion's Mane reduced amyloid plaques, tau proteins, and neuroinflammation markers (microglia down 19.4%, astrocytes down 43.3%) in preclinical models — attacking neurodegeneration on multiple fronts simultaneously.
- Amyloid accumulation can begin in cognitively normal adults in their mid-40s — decades before symptoms appear. Neuroprotection isn't for sick people. It's for everyone.
- No serious adverse events were reported across the entire 49-week duration — a safety profile that matches the urgency of the threat.
Why This Matters for You
You insure your car, your home, your business. But the single most irreplaceable asset you have — the brain that built everything you've achieved — typically gets zero protection. This study makes the case for changing that. The neurodegenerative processes that erode cognitive performance start silently, years before you notice them. Lion's Mane is the only dietary compound with clinical evidence showing it can push back.
Every executive carries insurance on their most valuable assets. Property. Liability. Key-person coverage. But the single most valuable asset in any executive's portfolio -- the brain that makes every decision, drives every strategy, and holds decades of accumulated expertise -- typically gets no protection at all.
In 2020, the longest clinical trial of Lion's Mane ever conducted provided evidence that this mushroom may function as exactly that: cognitive insurance.
The Longest Trial in Lion's Mane History
Published in Frontiers in Aging Neuroscience, the study led by I-Chen Li and colleagues was a double-blind, placebo-controlled trial spanning 49 weeks -- nearly a full year of daily supplementation. Patients with mild Alzheimer's disease received either erinacine A-enriched Lion's Mane mycelia capsules (three 350mg capsules daily, standardized to 5mg/g erinacine A) or placebo.
The duration alone makes this study exceptional. Most supplement trials run 4 to 16 weeks. Studying a compound for nearly a year provides a much clearer picture of both its long-term efficacy and its safety profile.
The Results: Diverging Trajectories
The data revealed two trajectories moving in opposite directions.
The Lion's Mane group showed significant improvement on the MMSE (Mini-Mental State Examination) -- the most widely used cognitive assessment in clinical practice. They also scored higher on the CASI (Cognitive Abilities Screening Instrument) and showed significant improvement on the IADL (Instrumental Activities of Daily Living), which measures the ability to perform complex daily tasks like managing finances, navigating transportation, and organizing medications.
The placebo group, meanwhile, showed significant decline in CASI scores over the same period. Their cognitive function was measurably eroding while the Lion's Mane group was improving.
This divergence is the study's most powerful finding. It is not simply that Lion's Mane slowed decline. The supplementation group was actually getting better while the control group was getting worse. Over 49 weeks, the gap between the two groups widened progressively.
The Preclinical Evidence: What Is Happening at the Cellular Level
The human trial results are supported by preclinical research that reveals what is happening inside the brain at a structural level.
In transgenic mice engineered to develop Alzheimer's-like pathology, erinacine A-enriched Lion's Mane produced striking results:
- Amyloid-beta plaques -- the hallmark protein deposits of Alzheimer's -- were significantly reduced.
- Phosphorylated tau -- another key marker of neurodegeneration -- was decreased.
- Microglia clusters decreased by 19.4% -- microglia are immune cells in the brain that, when overactivated, drive neuroinflammation.
- Astrocyte clusters decreased by 43.3% -- astrocytes, when reactive, are another indicator of brain inflammation.
Together, these findings suggest that Lion's Mane attacks neurodegenerative processes on multiple fronts: reducing toxic protein accumulation, dampening neuroinflammation, and protecting the cellular environment in which neurons operate.
Reframing Neuroprotection for Healthy Executives
It would be easy to dismiss this study as relevant only to Alzheimer's patients. That would be a mistake.
The neurodegenerative processes measured in the Li trial -- amyloid accumulation, tau phosphorylation, neuroinflammation -- do not begin the day someone receives an Alzheimer's diagnosis. They begin decades earlier, in the brains of otherwise healthy, high-functioning adults.
Research from the Alzheimer's Drug Discovery Foundation and longitudinal brain imaging studies have shown that amyloid plaques can begin accumulating as early as the mid-40s in cognitively normal individuals. By the time symptoms become noticeable, the underlying damage has been progressing silently for years.
For an executive in their 40s or 50s -- performing at the highest level, making critical decisions, managing complex organizations -- the relevant question is not "Do I have Alzheimer's?" It is "What am I doing to protect the cognitive infrastructure I have built over my entire career?"
The Insurance Analogy
No one buys fire insurance because they expect their building to burn down. They buy it because the asset is too valuable to leave unprotected against a risk that, while uncertain, would be catastrophic.
Cognitive decline follows the same logic. Most executives will not develop Alzheimer's disease. But many will experience some degree of age-related cognitive erosion -- slower processing, weaker recall, reduced mental stamina. The Li trial provides evidence that daily Lion's Mane supplementation may protect against this erosion while simultaneously improving current function.
The study's 49-week duration aligns with the reality of how neuroprotection works: it is not a quick fix. It is a long-term commitment that pays dividends in preserved cognitive capacity over years and decades.
The NTRL Approach
NTRL's Executive's Coffee delivers 300mg of Lion's Mane per capsule as a daily maintenance dose designed for consistent, long-term use. The Li trial reinforces what the Mori memory study also showed: Lion's Mane works best when taken regularly over extended periods. The subscription model exists because the science demands it -- not as a business convenience, but as a reflection of how the compound actually works.
Protecting your brain is not a one-time purchase. It is an ongoing commitment to the asset that makes everything else in your career possible.
Source: Li IC, Chang HH, Lin CH, et al. "Prevention of Early Alzheimer's Disease by Erinacine A-Enriched Hericium erinaceus Mycelia Pilot Double-Blind Placebo-Controlled Study." Frontiers in Aging Neuroscience. 2020;12:155. [PubMed 32581767](https://pubmed.ncbi.nlm.nih.gov/32581767/)